Organ and effective doses from verification techniques in image-guided radiotherapy

Evaluation of patient organ doses from kilovoltage cone-beam CT imaging in radiation therapy

Background

Currently, CBCT system is an indispensable component of radiation therapy units. Because of that, it is important in treatment planning and diagnosis. CBCT is also an crucial tool for patient positioning and verification in image-guided radiation therapy (IGRT). Therefore, it is critical to investigate the patient organ doses arising from CBCT imaging. The purpose of this study is to evaluate patient organ doses and effective dose to patients from three different protocols of Elekta Synergy XVI system for kV CBCT imaging examinations in image guided radiation therapy.

Materials and methods

Organ dose measurements were done with thermoluminescent dosimeters in Alderson RA NDO male phantom for head & neck (H&N), chest and pelvis protocols of the Elekta Synergy XVI kV CBCT system. From the measured organ dose, effective dose to patients were calculated according to the International Commission on Radiological Protection 103 report recommendations.

Results

For H&N, chest and pelvis scans, the organ doses were in the range of 0.03-3.43 mGy, 6.04-22.94 mGy and 2.5-25.28 mGy, respectively. The calculated effective doses were 0.25 mSv, 5.56 mSv and 4.72 mSv, respectively.

Conclusion

The obtained results were consistent with the most published studies in the literature. Although the doses to patient organs from the kV CBCT system were relatively low when compared with the prescribed treatment dose, the amount of delivered dose should be monitored and recorded carefully in order to avoid secondary cancer risk, especially in pediatric examinations.

A Monte Carlo study of organ and effective doses of cone beam computed tomography (CBCT) scans in radiotherapy

Cone-beam CT (CBCT) scans utilised for image guided radiation therapy (IGRT) procedures have become an essential part of radiotherapy. The aim of this study was to assess organ and effective doses resulting from new CBCT scan protocols (head, thorax, and pelvis) released with a software upgrade of the kV on-board-imager (OBI) system. Organ and effective doses for protocols of the new software (V2.5) and a previous version (V1.6) were assessed using Monte Carlo (MC) simulations for the International Commission on Radiological Protection (ICRP) adult male and female reference computational phantoms. The number of projections and the mAs values were increased and the size of the scan field was extended in the new protocols. Influence of these changes on organ and effective doses of the scans was investigated. The OBI system was modelled in EGSnrc/BEAMnrc, and organ doses were estimated using EGSnrc/DOSXYZnrc. The MC model was benchmarked against experimental measurements. Organ doses resulting from the V2.5 protocols were higher than those of V1.6 for organs that were partially or fully inside the scans fields, and increased by (3-13)%, (10-77)%, and (13-21)% for the head, thorax, and pelvis protocols for both phantoms, respectively. As a result, effective doses rose by 14%, 17%, and 16% for the male phantom, and 13%, 18%, and 17% for the female phantom for the three scan protocols, respectively. The scan field extension for the V2.5 protocols contributed significantly in the dose increases, especially for organs that were partially irradiated such as the thyroid in head and thorax scans and colon in the pelvic scan. The contribution of the mAs values and projection numbers was minimal in the dose increases, up to 2.5%. The field size extension plays a major role in improving the treatment output by including more markers in the field of view to match between CBCT and CT images and hence setting up the patient precisely. Therefore, a trade-off between the risk and benefits of CBCT scans should be considered, and the dose increases should be monitored. Several recommendations have been made for optimisation of the patient dose involved for IGRT procedures.

Determination of the effective dose delivered by image guided radiotherapy in head & neck and breast treatments

PURPOSE

Image guided radiotherapy (IGRT) improves patient positioning for treatment delivery at the cost of an additional dose. This work aimed to calculate the effective dose (as an indicator of dose) for head & neck (H&N) and breast IGRT treatments by implementing dose calculation models to determine the dose distributions.

METHODS

The kV dose-models were created for the IGRT systems of Elekta Synergy (XVI) and Varian Clinac (OBI) linear accelerators within Philips Pinnacle TPS. Profiles and depth dose curves were measured in water. The models were validated in a CIRS thorax phantom. The IGRT dose distributions for five H&N and five breast patients were calculated. The effective dose was determined from the dose distributions following ICRP 103 recommendations. Moreover, time-saving approximations were studied in order to propose an alternative way of segmenting the tissues for a clinical implementation of the method.

RESULTS AND CONCLUSION

The effective dose specifically associated with IGRT varied from 1 to 10mSv depending on the protocol. The kV dose-model allowed us to calculate the dose distributions from IGRT for different configurations and patients, and to determine effective dose for IGRT protocols. The clinical implementation of the method was found to reduce time and to introduce a small enough increase of uncertainty in the results to be clinically usable.

Comprehensive Monte Carlo study of patient doses from cone-beam CT imaging in radiotherapy

Accurate knowledge of ionizing radiation dose from cone-beam CT (CBCT) imaging in radiotherapy is important to allow concomitant risks to be estimated and for justification of imaging exposures. This study uses a Monte Carlo CBCT model to calculate imaging dose for a wide range of imaging protocols for male and female patients. The Elekta XVI CBCT system was modeled using GATE and simulated doses were validated against measurements in a water tank and thorax phantom. Imaging dose was simulated in the male and female ICRP voxel phantoms for a variety of anatomical sites and imager settings (different collimators, filters, full and partial rotation). The resulting dose distributions were used to calculate effective doses for each scan protocol. The Monte Carlo simulated doses agree with validation measurements within 5% and 10% for water tank and thorax phantom respectively. Effective dose for head CBCT scans was generally lower for scans centred on the pituitary than the larynx (0.03 mSv versus 0.06 mSv for male ICRP phantom). Pelvis CBCT scan effective dose was higher for the female than male phantom (5.11 mSv versus 2.80 mSv for M15 collimator scan), principally due to the higher dose received by gonads for the female scan. Medium field of view thorax scan effective doses ranged from 1.38-3.19 mSv depending on scan length and phantom sex. Effective dose for half rotation thorax scans with offset isocentre varied by almost a factor of three depending on laterality of the isocentre, patient sex and imaged field length. The CBCT imaging doses simulated here reveal large variations in dose depending on imaging isocentre location, patient sex and partial rotation angles. This information may be used to estimate risks from CBCT and to optimize CBCT imaging protocols.

Imaging dose from cone beam computed tomography in radiation therapy

Imaging dose in radiation therapy has traditionally been ignored due to its low magnitude and frequency in comparison to therapeutic dose used to treat patients. The advent of modern, volumetric, imaging modalities, often as an integral part of linear accelerators, has facilitated the implementation of image-guided radiation therapy (IGRT), which is often accomplished by daily imaging of patients. Daily imaging results in additional dose delivered to patient that warrants new attention be given to imaging dose. This review summarizes the imaging dose delivered to patients as the result of cone beam computed tomography (CBCT) imaging performed in radiation therapy using current methods and equipment. This review also summarizes methods to calculate the imaging dose, including the use of Monte Carlo (MC) and treatment planning systems (TPS). Peripheral dose from CBCT imaging, dose reduction methods, the use of effective dose in describing imaging dose, and the measurement of CT dose index (CTDI) in CBCT systems are also reviewed.

Radiation burden from secondary doses to patients undergoing radiation therapy with photons and light ions and radiation doses from imaging modalities

Ionising radiation is increasingly used for the treatment of cancer, being the source of a considerable fraction of the medical irradiation to patients. With the increasing success rate of cancer treatments and longer life expectancy of the treated patients, the issue of secondary cancer incidence is of growing concern, especially for paediatric patients who may live long after the treatment and be more susceptible to carcinogenesis. Also, additional imaging procedures like computed tomography, kilovoltage and megavoltage imaging and positron emission tomography, alone or in conjunction with radiation therapy, may add to the radiation burden associated with the risk of occurrence of secondary cancers. This work has been based on literature studies and is focussed on the assessment of secondary doses to healthy tissues that are delivered by the use of modern radiation therapy and diagnostic imaging modalities in the clinical environment.

Evaluation of radiation dose to organs during kilovoltage cone-beam computed tomography using Monte Carlo simulation

Image-guided techniques for radiation therapy have improved the precision of radiation delivery by sparing normal tissues. Cone-beam computed tomography (CBCT) has emerged as a key technique for patient positioning and target localization in radiotherapy. Here, we investigated the imaging radiation dose delivered to radiosensitive organs of a patient during CBCT scan. The 4D extended cardiac-torso (XCAT) phantom and Geant4 Application for Tomographic Emission (GATE) Monte Carlo (MC) simulation tool were used for the study. A computed tomography dose index (CTDI) standard polymethyl methacrylate (PMMA) phantom was used to validate the MC-based dosimetric evaluation. We implemented an MC model of a clinical on-board imager integrated with the Trilogy accelerator. The MC model's accuracy was validated by comparing its weighted CTDI (CTDIw) values with those of previous studies, which revealed good agreement. We calculated the absorbed doses of various human organs at different treatment sites such as the head-and-neck, chest, abdomen, and pelvis regions, in both standard CBCT scan mode (125 kVp, 80 mA, and 25 ms) and low-dose scan mode (125 kVp, 40 mA, and 10 ms). In the former mode, the average absorbed doses of the organs in the head and neck and chest regions ranged 4.09-8.28 cGy, whereas those of the organs in the abdomen and pelvis regions were 4.30-7.48 cGy. In the latter mode, the absorbed doses of the organs in the head and neck and chest regions ranged 1.61-1.89 cGy, whereas those of the organs in the abdomen and pelvis region ranged between 0.79-1.85 cGy. The reduction in the radiation dose in the low-dose mode compared to the standard mode was about 20%, which is in good agreement with previous reports. We opine that the findings of this study would significantly facilitate decisions regarding the administration of extra imaging doses to radiosensitive organs.

Imaging doses and secondary cancer risk from kilovoltage cone-beam CT in radiation therapy

The authors assessed the radiation-induced cancer risk due to organ doses from kilovoltage (kV) cone beam computed tomography (CBCT), a verification technique in image-guided radiotherapy (IGRT). CBCTs were performed for three different treatment sites: the head and neck, chest, and pelvis. Using a glass dosimeter, primary doses versus depth were measured inside a homemade phantom, and organ doses were measured at various locations inside an anthropomorphic phantom. The excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) for cancer induction were estimated using the BEIR VII models based on dose measurement. The average primary (i.e., in-field) doses at the center of the phantom for standard imaging options were 1.9, 5.1, and 16.7 cGy for the head and neck, chest, and pelvis, respectively. The average secondary dose per scan for the pelvis measured 20-50 cm from the isocenter and ranged from 0.67-0.02 cGy, whereas the secondary dose per scan for the head and neck ranged from 0.07-0.003 cGy, indicating that CBCT for treatment of the head and neck is associated with a smaller secondary radiation dose than CBCT for treatment of the pelvis. The estimation of LAR from CBCT in IGRT indicated that the lifetime cancer risk for major organs can reach approximately 400 per 10,000 persons if 30 CBCT scans are performed to position a patient during radiation treatment of the pelvis site.